Mitotane is used in adrenal cancer as adjuvant therapy, monotherapy or combined with other cytotoxic agents in advanced disease.
Side-effects include drug-induced hypoadrenocorticism.
Recommended dose rate in dogs is 50 mg/kg orally once daily for five days, then once weekly maintenance therapy. However, as body weight increases, dose/kg or dosage/day of trilostane required to control the clinical signs of PDH decreases. Dogs weighing >30 kg might require smaller amounts of trilostane per dose or per day.
- Reine NJ (2012) Medical management of pituitary-dependent hyperadrenocorticism: mitotane versus trilostane. Top Companion Anim Med 27(1):25-30
- Feldman EC & Kass PH (2012) Trilostane dose versus body weight in the treatment of naturally occurring pituitary-dependent hyperadrenocorticism in dogs. J Vet Intern Med 26(4):1078-1080